TCG Crossover Management
Latest statistics and disclosures from TCG Crossover Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, CGON, COGT, AMLX, CNTA, and represent 49.69% of TCG Crossover Management's stock portfolio.
- Added to shares of these 10 stocks: ABVX (+$90M), LQDA (+$39M), AGIO (+$29M), Lb Pharmaceuticals (+$28M), RVMD (+$20M), KRRO (+$20M), SYRE (+$18M), URGN (+$14M), ARVN (+$14M), MNPR (+$13M).
- Started 11 new stock positions in RVMD, LQDA, ADCT, KRRO, SYRE, PEPG, RLAY, Lb Pharmaceuticals, MNPR, URGN. ARVN.
- Reduced shares in these 10 stocks: CDTX (-$49M), TNGX (-$19M), SLNO (-$16M), UPB (-$13M), THRD (-$10M), ELVN (-$10M), TRML (-$7.9M), NKTR (-$6.9M), KURA, COGT.
- Sold out of its positions in JBIO, CABA, CDTX, ELVN, KROS, KURA, NKTR, SLNO, THRD.
- TCG Crossover Management was a net buyer of stock by $203M.
- TCG Crossover Management has $2.0B in assets under management (AUM), dropping by 132.20%.
- Central Index Key (CIK): 0001839948
Tip: Access up to 7 years of quarterly data
Positions held by TCG Crossover Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for TCG Crossover Management
TCG Crossover Management holds 40 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax Sa American Depositary Shares Adrs (ABVX) | 29.7 | $604M | +17% | 7.1M | 84.90 |
|
| Cg Oncology Comm (CGON) | 7.3 | $148M | 3.7M | 40.28 |
|
|
| Cogent Biosciences Comm (COGT) | 4.8 | $98M | -2% | 6.8M | 14.36 |
|
| Amylyx Pharmaceuticals Comm (AMLX) | 4.2 | $85M | +5% | 6.2M | 13.59 |
|
| Centessa Pharmaceuticals Adrs (CNTA) | 3.7 | $76M | +8% | 3.1M | 24.25 |
|
| Tango Therapeutics Comm (TNGX) | 3.5 | $72M | -20% | 8.5M | 8.40 |
|
| Ocular Therapeutix Comm (OCUL) | 3.5 | $72M | +15% | 6.1M | 11.69 |
|
| Dianthus Therapeutics Comm (DNTH) | 3.2 | $66M | +11% | 1.7M | 39.35 |
|
| Tourmaline Bio Comm (TRML) | 3.1 | $63M | -11% | 1.3M | 47.83 |
|
| Dyne Therapeutics Comm (DYN) | 2.9 | $58M | +22% | 4.6M | 12.65 |
|
| Agios Pharmaceuticals Comm (AGIO) | 2.8 | $57M | +105% | 1.4M | 40.14 |
|
| Eyepoint Pharmaceuticals Comm (EYPT) | 2.5 | $51M | 3.6M | 14.24 |
|
|
| Fulcrum Therapeutics Comm (FULC) | 2.4 | $48M | 5.3M | 9.20 |
|
|
| Savara Comm (SVRA) | 2.2 | $44M | 12M | 3.57 |
|
|
| Rapt Therapeutics Comm (RAPT) | 2.1 | $42M | 1.6M | 25.79 |
|
|
| Tyra Biosciences Comm (TYRA) | 2.0 | $41M | 2.9M | 13.99 |
|
|
| Upstream Bio Comm (UPB) | 2.0 | $40M | -24% | 2.1M | 18.81 |
|
| Liquidia Technologies Comm (LQDA) | 1.9 | $39M | NEW | 1.7M | 22.74 |
|
| Disc Medicine Comm (IRON) | 1.5 | $31M | 465k | 66.08 |
|
|
| Structure Therapeutics Adrs (GPCR) | 1.5 | $30M | 1.1M | 28.00 |
|
|
| Xencor Comm (XNCR) | 1.4 | $29M | 2.5M | 11.73 |
|
|
| Lb Pharmaceuticals Comm | 1.4 | $28M | NEW | 1.7M | 15.79 |
|
| Revolution Medicines Comm (RVMD) | 1.0 | $20M | NEW | 437k | 46.70 |
|
| Astria Therapeutics Comm (ATXS) | 1.0 | $20M | 2.8M | 7.28 |
|
|
| Korro Bio Comm (KRRO) | 1.0 | $20M | NEW | 416k | 47.89 |
|
| Kodiak Sciences Comm (KOD) | 0.9 | $19M | 1.1M | 16.37 |
|
|
| Spyre Therapeutics Comm (SYRE) | 0.9 | $18M | NEW | 1.1M | 16.76 |
|
| Silence Therapeutics Adrs (SLN) | 0.8 | $16M | 3.0M | 5.19 |
|
|
| Urogen Pharma Comm (URGN) | 0.7 | $14M | NEW | 717k | 19.95 |
|
| Arvinas Holding Comm (ARVN) | 0.7 | $14M | NEW | 1.6M | 8.52 |
|
| Monopar Therapeutics Comm (MNPR) | 0.6 | $13M | NEW | 153k | 81.67 |
|
| Mbx Biosciences Comm (MBX) | 0.6 | $11M | 650k | 17.50 |
|
|
| Vistagen Therapeutics Comm (VTGN) | 0.5 | $9.5M | 2.7M | 3.55 |
|
|
| Relay Therapeutics Comm (RLAY) | 0.5 | $9.5M | NEW | 1.8M | 5.22 |
|
| Adverum Biotechnologies Comm (ADVM) | 0.4 | $7.6M | -7% | 1.7M | 4.53 |
|
| Avalo Therapeutics Comm (AVTX) | 0.3 | $6.1M | 483k | 12.71 |
|
|
| Adc Therapeutics Sa Comm (ADCT) | 0.3 | $5.6M | NEW | 1.4M | 4.00 |
|
| Pepgen Comm (PEPG) | 0.3 | $5.5M | NEW | 1.2M | 4.62 |
|
| Entrada Therapeutics Comm (TRDA) | 0.2 | $3.4M | 585k | 5.80 |
|
|
| Ventyx Biosciences Comm (VTYX) | 0.0 | $983k | 316k | 3.11 |
|
Past Filings by TCG Crossover Management
SEC 13F filings are viewable for TCG Crossover Management going back to 2021
- TCG Crossover Management 2025 Q3 filed Nov. 17, 2025
- TCG Crossover Management 2025 Q2 filed Aug. 14, 2025
- TCG Crossover Management 2025 Q1 filed May 14, 2025
- TCG Crossover Management 2024 Q4 filed Feb. 14, 2025
- TCG Crossover Management 2024 Q3 filed Nov. 14, 2024
- TCG Crossover Management 2024 Q2 filed Aug. 14, 2024
- TCG Crossover Management 2024 Q1 filed May 15, 2024
- TCG Crossover Management 2023 Q4 filed Feb. 14, 2024
- TCG Crossover Management 2023 Q3 filed Nov. 14, 2023
- TCG Crossover Management 2023 Q2 filed Aug. 14, 2023
- TCG Crossover Management 2023 Q1 filed May 15, 2023
- TCG Crossover Management 2022 Q4 filed Feb. 14, 2023
- TCG Crossover Management 2022 Q3 filed Nov. 14, 2022
- TCG Crossover Management 2022 Q2 filed Aug. 15, 2022
- TCG Crossover Management 2022 Q1 filed May 16, 2022
- TCG Crossover Management 2021 Q4 filed Feb. 18, 2022